【摘要】：觀察恩替卡韋聯(lián)合細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞(cytokine-induced kill cells,CIK)序貫治療慢性乙型肝炎患者DC功能變化,為指導(dǎo)CIK聯(lián)合核苷(類)藥物抗病毒治療提供理論依據(jù)。以15例接受恩替卡韋聯(lián)合CIK序貫治療的慢性乙型肝炎患者為觀察對(duì)象,單獨(dú)接受CIK治療患者為對(duì)照,分別在治療前、HBVDNA500IU/ml及CIK治療2周后流式細(xì)胞技術(shù)測(cè)定DC表面共刺激分子CD1a、CD80、CD83及HLA-DR表達(dá)水平,同時(shí)淋巴細(xì)胞增殖實(shí)驗(yàn)評(píng)估DC細(xì)胞功能。結(jié)果顯示15例恩替卡韋聯(lián)合CIK序貫治療患者同治療前相比在接受恩替卡韋治療并達(dá)到HBVDNA500IU/ml時(shí)僅有HLA-DR表達(dá)水平高于治療前,其它共刺激分子標(biāo)志物及淋巴細(xì)胞增殖能力沒(méi)有顯著變化。CIK序貫治療后DC共刺激分子標(biāo)志物和HLA-DR水平明顯升高,并且淋巴細(xì)胞增殖能力也明顯升高。單獨(dú)CIK治療患者同治療前比較DC表面分子標(biāo)志物水平及淋巴細(xì)胞增殖能力均無(wú)變化,同聯(lián)合治療組相比DC標(biāo)志物水平和淋巴細(xì)胞增殖能力均低于聯(lián)合治療組。以上結(jié)果提示恩替卡韋聯(lián)合CIK序貫治療明顯提高慢性乙型肝炎患者DC共刺激分子及HLA-DR表達(dá),并誘導(dǎo)免疫細(xì)胞應(yīng)答功能,恩替卡韋聯(lián)合CIK序貫治療可能通過(guò)增強(qiáng)DC相關(guān)功能提高慢性乙肝患者的抗病毒療效。
[Abstract]:To observe the changes of DC function in patients with chronic hepatitis B treated by entecavir combined with cytokine induced killer cells (cytokine-induced kill cells,CIK), and to provide a theoretical basis for the guidance of CIK combined with nucleoside (nucleoside) antiviral therapy. Fifteen patients with chronic hepatitis B who received entecavir plus CIK sequential therapy, and 15 patients treated with CIK alone as control, were observed before treatment. After two weeks of treatment with HBVDNA500IU/ml and CIK, the expression levels of CD1a,CD80,CD83 and HLA-DR on DC surface were measured by flow cytometry, and the function of DC cells was evaluated by lymphocyte proliferation assay. The results showed that the expression level of HLA-DR in 15 patients with entecavir combined with CIK was higher than that before treatment when they were treated with entecavir and reached HBVDNA500IU/ml. There was no significant change in other costimulatory molecular markers and lymphocyte proliferation ability. After CIK sequential therapy, the levels of DC costimulatory molecular markers and HLA-DR were significantly increased, and the lymphocyte proliferation ability was also significantly increased. There was no change in the level of DC surface molecular markers and lymphocyte proliferation in patients treated with CIK alone. Compared with the combined treatment group, the level of DC markers and the ability of lymphocyte proliferation were lower than those of the combined treatment group. These results suggest that the sequential therapy of entecavir and CIK can significantly increase the expression of DC costimulatory molecules and HLA-DR and induce immune cell response in patients with chronic hepatitis B. Entecavir combined with CIK sequential therapy may enhance the antiviral efficacy of chronic hepatitis B patients by enhancing DC related function.
【作者單位】： 南京軍區(qū)福州總醫(yī)院感染科;福建醫(yī)科大學(xué)�？偱R床醫(yī)學(xué)院傳染病學(xué)教研室;
【基金】：福建省自然科學(xué)基金項(xiàng)目(2011J01236)
【分類號(hào)】：R512.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 陳月;陳洪濤;吳詩(shī)品;周雅瑩;方愛(ài)萍;;阿德福韋酯對(duì)慢性乙型肝炎患者外周血樹(shù)突狀細(xì)胞和淋巴細(xì)胞亞群的影響[J];廣東醫(yī)學(xué);2010年01期

2 莊捷;曹暉;劉祥麟;張尚權(quán);;樹(shù)突狀細(xì)胞與CIK細(xì)胞共培養(yǎng)誘生的DCCIK細(xì)胞群對(duì)腫瘤的殺傷作用[J];細(xì)胞生物學(xué)雜志;2007年02期

3 韓際奧;楊麗;王志凌;韓莉;王郁杰;馬英杰;;慢性乙型肝炎患者DC/CIK體外經(jīng)HBsAg活化后自體回輸?shù)寞熜Ш蛯?duì)機(jī)體免疫的影響[J];中華實(shí)驗(yàn)和臨床感染病雜志(電子版);2013年03期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 侯金程;楊麗輝;楊琨;谷京城;;樹(shù)突狀細(xì)胞疫苗聯(lián)合細(xì)胞因子誘導(dǎo)的殺傷細(xì)胞治療鼻腔及鼻竇惡性黑色素瘤的近期療效觀察[J];臨床醫(yī)學(xué);2010年01期

2 程巖;耿家寶;隋云華;張s，

本文編號(hào)：2297672